Shionogi Reports Results of Phase III Clinical Trials of the Idiopathic ...

Back

Tokyo, Japan, Dec 26, 2006 - (JCN) - Shionogi announced on December 22 that it has achieved the primary objectives of Phase III clinical trials for the idiopathic

1. Of or relating to a disease having no known cause; agnogenic.

2. Of or relating to a disease that is not the result of any other disease.

 pulmonary fibrosis treatment S-7701, generic name pirfenidone, which the Company is developing in Japan under a license from U.S.-based Marnac, Inc. and KDL KDL - KD Lang (musician)
KDL - Kent District Library (Michigan), Inc., Tokyo.

Idiopathic pulmonary fibrosis (IPF IPF - Idiopathic Pulmonary Fibrosis
IPF - Illegal Page Fault
IPF - Imagery Processing Facility
IPF - Impact-Producing Factor
IPF - In-Print Forever (Artech House)
IPF - Information Presentation Facility
IPF - Information Processing Facility
IPF - Initial Production Facilities
IPF - Innovation Possibilities Frontier
IPF - Inpatient Psychiatric Facility
IPF - Institute of Public Finance (UK)
IPF - Instructions Per Fetch) is a medical condition of unknown etiology with poor prognosis in which progressive fibrosis of the alveolar alveolar /al·ve·o·lar/ (al-ve´o-lar) [L. alveolaris ] pertaining to an alveolus.

---

al·ve·o·lar (l-v walls produces irreversible "honeycomb lung hon·ey·comb lung (hn-km", in which a high-resolution CT scan of the lung yields a honeycomb pattern.

In general, restrictive impairment, orreduction of vital capacity (VC) and total lung capacity (TLC), is evident. As the symptom - fibrosis of the alveolar walls - progresses, gas exchange in the lungs, the exchange of oxygen and carbon dioxide,

becomes difficult. In some cases, oxygen therapy becomes necessary. Because of its severity, IPF is designated as a "specified disease", in other words, an intractable disorder.

Under development as a treatment for IPF, S-7701 has been designated as an orphan drug, or a drug used to treat a rare disease, by the Pharmaceuticals and Medical Devices Agency.

In the Phase III clinical trials for this drug with VC change (from before commencement of treatment to 52 weeks after commencing treatment) as the primary endpoint, both high and low doses of the drug (600mgl per day, three times a day and 400mgl per day, three times a day, respectively), significantly inhibited worsening of the condition compared with a placebo.

While continuing to conduct further analysis and study, Shionogi plans to expedite the application process based on these clinical results, with the intention of submitting a new drug application (NDA) within the current fiscal year.

Copyright [c] 2006 Japan Corporate News Network. All rights reserved.